InvestSMART

Radiopharm Theranostics Limited (ASX: RAD) - Announcements

Current share price for RAD : $0.011 0.001 (10%)+

ASX company news and announcements for Radiopharm Theranostics Limited (RAD) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Radiopharm Theranostics Limited (RAD) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Radiopharm Theranostics Limited (RAD), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Radiopharm Theranostics Limited (RAD)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$48 Notice Under Section 708A 16 May 2024 4:27PM $0.040 $0.011 fallen by 72.15%
$48 Application for quotation of securities - RAD 16 May 2024 4:18PM $0.040 $0.011 fallen by 72.15%
$48 RAD to be featured at B. Riley Securities Healthcare events 8 May 2024 2:27PM $0.039 $0.011 fallen by 71.79%
$48 Quarterly Activities/Appendix 4C Cash Flow Report 30 Apr 2024 9:19AM $0.045 $0.011 fallen by 75.56%
$48 Notification regarding unquoted securities - RAD 24 Apr 2024 5:22PM $0.045 $0.011 fallen by 75.56%
$48 Radiopharm Ventures institutional & VC presentation 22 Apr 2024 12:12PM $0.046 $0.011 fallen by 76.09%
$48 Notice Under Section 708A 15 Apr 2024 4:35PM $0.046 $0.011 fallen by 76.09%
$48 Application for quotation of securities - RAD 15 Apr 2024 4:32PM $0.046 $0.011 fallen by 76.09%
$48 Results of Extraordinary General Meeting 15 Apr 2024 11:26AM $0.050 $0.011 fallen by 78%
$48 Presentation to Extraordinary General Meeting 15 Apr 2024 9:01AM $0.047 $0.011 fallen by 76.60%
$48 Initial Director's Interest Notice PH 26 Mar 2024 5:49PM $0.057 $0.011 fallen by 80.70%
$48 Final Director's Interest Notice MB 26 Mar 2024 5:48PM $0.057 $0.011 fallen by 80.70%
$48 Board Changes 26 Mar 2024 10:18AM $0.058 $0.011 fallen by 81.03%
$48 RAD to present at NWR Virtual Healthcare Conference 19 Mar 2024 9:23AM $0.060 $0.011 fallen by 81.67%
$48 RAD 301 and 302 data shows value of targeting avb6-integrin 15 Mar 2024 9:30AM $0.060 $0.011 fallen by 81.67%
$48 Notice of Extraordinary General Meeting/Proxy Form 15 Mar 2024 9:01AM $0.060 $0.011 fallen by 81.67%
$48 Notice Under Section 708A 12 Mar 2024 5:53PM $0.058 $0.011 fallen by 81.03%
$48 Application for quotation of securities - RAD 12 Mar 2024 5:51PM $0.058 $0.011 fallen by 81.03%
$48 Multiple RAD301 data releases to be presented at EMIM 6 Mar 2024 10:26AM $0.064 $0.011 fallen by 82.81%
$48 Notice Under Section 708A 4 Mar 2024 3:46PM $0.067 $0.011 fallen by 83.58%
$48 Application for quotation of securities - RAD 4 Mar 2024 3:28PM $0.069 $0.011 fallen by 84.06%
$48 B Riley Securities Radiopharma Conference Presentation 4 Mar 2024 8:52AM $0.067 $0.011 fallen by 83.58%
$48 Half Yearly Report and Accounts 29 Feb 2024 2:42PM $0.065 $0.011 fallen by 83.08%
$48 Dosing begins in Phase 1 Pancreatic Imaging Study of RAD 301 29 Feb 2024 9:20AM $0.056 $0.011 fallen by 80.36%
$48 Pilot Study Validates RAD Terbium-161 Radiotherapeutics 28 Feb 2024 9:52AM $0.057 $0.011 fallen by 80.70%

226 - 250 of 613 results

Page 10 of 25

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.